Price
No data yet.
Social Signal Score
Revenue
$7.19M+265.13%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- F. Olivier Te Boekhorst
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Beta
- 0.55
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.29
Financials
Revenue
$7.19M+265.1%Net Income
$1.83M+5161.4%EBITDA
$2.45M+874.6%Free Cash Flow
$2.29MEPS (diluted)
$0.20+1900.0%Shares Outstanding (diluted)
9.19M+113.6%Operating Expenses
$2.50MCash & Debt
$8.86MRevenue by Segment (annual)
$19.24MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $27.64M | $-1.04M | $-0.12 |
| 2024 | $26.49M | $-2.16M | $-0.26 |
| 2023 | $17.47M | $-5.77M | $-0.75 |
| 2022 | $18.57M | $-2.49M | $-0.32 |
| 2021 | $19.24M | $-78.3K | $-0.01 |
| 2020 | $15.34M | $-1.02M | $-0.14 |
| 2019 | $13.72M | $-1.30M | $-0.19 |
| 2018 | $10.99M | $-2.32M | $-0.42 |
| 2017 | $10.43M | $-168.0K | $-0.03 |
| 2016 | $9.54M | $508.4K | $0.12 |
| 2015 | $10.23M | $1.21M | $0.40 |
| 2014 | $7.60M | $-167.2K | $-0.06 |
| 2013 | $6.01M | $117.4K | $0.04 |
| 2012 | $5.39M | $89.5K | $0.03 |
Valuation
ICCChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (4)
- Newszacks.com·39d ago·Neutral
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2 ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·52d ago·Positive
ImmuCell Q2 Earnings Call Highlights ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $0.05 per share
Typical surprise +300.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.20 vs $0.05beat
- Thu, May 14$0.21 vs $0.05beat
- Wed, Mar 4$-0.31 vs $-0.01miss
Estimates and results for ICCC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ICCC officers and directors.
- Bought
- $178k
- Sold
- —
9 trades
0 trades
- Te Boekhorst Paul Francis Olivierbought
- Te Boekhorst Paul Francis Olivierbought
- Te Boekhorst Paul Francis Olivierbought
- Te Boekhorst Paul Francis Olivierbought
- Te Boekhorst Paul Francis Olivierbought
- Te Boekhorst Paul Francis Olivierbought
- Tomsche David Scottbought
- Tomsche David Scottbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ICCC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.